Vir Biotechnology Inc expected to post earnings of 33 cents a share - Earnings Preview

Vir Biotechnology

03/08/2026 23:39

Vir Biotechnology Inc VIR.OQ VIR.O is expected to  show a rise in quarterly revenue when it reports  results on August 5 for the period ending June 30 2026
The San Francisco California-based  company is expected to report a 17,730.0% increase in revenue to $216.456 million from $1.21 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data. (Majority of Revenue includes collaboration with Astellas)
​LSEG's mean analyst estimate for Vir Biotechnology Inc is for earnings of 33 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Vir Biotechnology Inc is $21.00, about 136% above its last closing price of $8.90
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.11
-0.10
-0.85
Missed
-791
Dec. 31 2026
-0.52
-0.49
-0.31
Beat
36.9
Sep. 30 2025
-0.89
-0.85
-1.17
Missed
-37.1​
Jun. 30 2025
-0.73
-0.72
-0.80
Missed
-10.6
​​Mar. 31 2025
-0.82
-0.84
-0.88
Missed
-5.3
Dec. 31 2024
-0.87
-0.87
-0.76
Beat
12.9​
Sep. 30 2024
-1.07
-1.05
-1.56
Missed
-48.2
Jun. 30 2024
-0.88
-0.90
-1.02
Missed
-13.9
This summary was machine generated August 3 at 22:39 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)